

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Cambridge, UK – 18 July 2019– Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today held its Annual General Meeting (AGM), on second convening, following the default of quorum at the first General Meeting dated 19 June 2020, on the same agenda.

In the absence of a quorum for extraordinary resolutions, only ordinary resolutions were voted.

The results of the AGM are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:

Resolutions	Votes For		Votes Against		Result
	Number	%	Number	%	
1) Approval of the parent company financial statements for the 2018 financial year	4,803,930	76.7%	1,461,313	23.3%	yes
2) Approval of the consolidated financial statements for the 2018 financial year	6,265,296	100%	0	0%	yes
3) Allocation of the result for the 2018 financial year	6,265,296	100%	0	0%	yes
4) Review of the conventions referred to in article L. 225 – 38 and following of the French Commercial Code (without the vote of Vatel)	3,734,387	59.6%	2,530,909	41.4%	yes
5) Discharge to the Board of Directors	6,265,296	100%	0	0%	yes
6) Authorisation of the Company to buy back its own shares	3,734,027	59.59%	2,531,269	41.41%	yes
7) Determination of directors' fees to be allocated to the members of the Board of Directors	6,264,936	99.99%	360	0.01	yes
8) Powers for formalities	6,265,296	100%	0	0%	yes

Number of participating shareholders (by voting form, proxy or present): 41 shareholders representing 6,265,296 shares.

- End -

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across

an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com